Fulgent Genetics Inc. (FLGT) and DarioHealth Corp. (NASDAQ:DRIO) Contrasting side by side

Fulgent Genetics Inc. (NASDAQ:FLGT) and DarioHealth Corp. (NASDAQ:DRIO) are two firms in the Medical Laboratories & Research that compete against each other. Below is a comparison of their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fulgent Genetics Inc. 19.96M 3.78 5.18M -0.29 0.00
DarioHealth Corp. 7.27M 3.65 16.83M -1.73 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Fulgent Genetics Inc. and DarioHealth Corp.

Profitability

Table 2 shows Fulgent Genetics Inc. and DarioHealth Corp.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Fulgent Genetics Inc. -25.95% -9.8% -9.3%
DarioHealth Corp. -231.50% -394% -260.3%

Liquidity

Fulgent Genetics Inc.’s Current Ratio is 18.2 while its Quick Ratio is 18.2. On the competitive side is, DarioHealth Corp. which has a 3.4 Current Ratio and a 3.2 Quick Ratio. Fulgent Genetics Inc. is better positioned to pay off short and long-term obligations compared to DarioHealth Corp.

Institutional & Insider Ownership

Roughly 8.3% of Fulgent Genetics Inc. shares are owned by institutional investors while 10% of DarioHealth Corp. are owned by institutional investors. 38.5% are Fulgent Genetics Inc.’s share owned by insiders. Insiders Comparatively, owned 11.4% of DarioHealth Corp. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Fulgent Genetics Inc. -6.76% -3.22% -15.13% -13.2% -9.32% -24.43%
DarioHealth Corp. 3.38% -32.3% -22.73% -50.32% -47.96% -52.25%

For the past year Fulgent Genetics Inc. was less bearish than DarioHealth Corp.

Summary

Fulgent Genetics Inc. beats on 10 of the 10 factors DarioHealth Corp.

Fulgent Genetics, Inc., a technology company, focuses on providing genetic testing services to physicians with clinically actionable diagnostic information. The companyÂ’s technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. It primarily serves hospitals and medical institutions. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. Its flagship product is Dario, a mobile, real-time, cloud-based, diabetes management solution based on a multi-feature software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. The company is also pursuing patent applications in various jurisdictions covering the specific processes related to blood glucose level measurement, as well as various general methods of rapid tests of body fluids using mobile devices and cloud-based services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. The company was founded in 2011 and is headquartered in Caesarea, Israel.